Getinge CEO *TOMORROW* Barclays Conversations with the C-Suite in European Healthcare 2026

Research evidence excerpt

Getinge CEO *TOMORROW* Barclays Conversations with the C-Suite in European Healthcare 2026

Jon Unwin is a Vice President and research analyst

covering the European Medical Technologies & Services

sector. He joined Barclays in 2025, having previously

worked at Bernstein covering Medtech and before that

covering Capital Goods and Oil Services. He is currently

studying for an MSc in Health Economics, Policy and

Management from LSE and is a Chartered Accountant. Jon

began his career at EY in Assurance and has a Bachelor’s

degree in Maths with Mathematical Physics from UCL.

View Analyst Page

James Gordon is a Director and Head of the European

Pharma & Biotech Equity Research team at Barclays.

James joined Barclays in November 2025, having spent

c.20 years covering European Pharma & Biotech at J.P.

Morgan, where he was part of a team consistently top

ranked in the Institutional Investor / Extel survey. Prior to

Healthcare Equity Research James worked in Strategy

Consulting, focusing on Pharmaceuticals. James holds a

1st-class BSc in Genetics from University College London,

with a focus on Population Genetics and Statistics.

Charles Pitman-King joined Barclays in 2022 as a VP in the

European pharmaceutical team to cover a selection of

mid-cap companies. His previous experience includes

covering both mid-cap European and large-cap US

pharmaceutical companies since 2018, as well as broad

sector themes, such as the rapidly evolving COVID-19

pandemic and sector ESG themes. Prior to this, he has also

had experience covering the Aerospace and Defence

sector, and working in financial modelling. He holds a first

class Masters in Mathematics from Durham University and

has been a CFA charterholder since 2019.

Yihan Li, PhD, is a Vice President in the European